Tvardi Therapeutics, Inc. (TVRD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Tvardi Therapeutics reported revenue of $0, down 100.0% from $7.1M the year before. Net income was -$18.2M, or -$3.26 per diluted share. Operating activities generated -$23.5M of cash, leaving -$23.5M of free cash flow. At fiscal year end, Tvardi Therapeutics held $32.1M in total assets against $11.1M in total liabilities, including $20.7M of cash and equivalents.
Open the full interactive Tvardi Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Tvardi Therapeutics Key Stats
| Share Price | $1.04 |
|---|---|
| Market Cap | $9.8M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $1.03 – $7.00 |
| Shares Outstanding | 9.4 million (basic, 2026 Q2) |
Tvardi Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $135.1M | $23.0M | $41.9M | $21.0M | $7.1M | $0 |
| Cost of Goods Sold | — | $0 | — | — | — | — |
| Gross Profit | — | $23.0M | — | — | — | — |
| Operating Income | $5.4M | -$89.1M | -$87.5M | -$121.5M | -$58.4M | -$26.7M |
| Pre-Tax Income | $7.7M | -$88.4M | -$85.5M | -$118.5M | -$71.3M | -$18.2M |
| Income Tax | -$691,000 | $0 | $0 | $0 | -$398,000 | $0 |
| Net Income | $8.4M | -$88.4M | -$85.5M | -$118.5M | -$70.9M | -$18.2M |
| Diluted EPS | $6.48 | -$62.64 | -$57.24 | -$78.84 | -$46.59 | -$3.26 |
Tvardi Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 |
| Net Income | -$5.5M | -$11.9M | -$6.8M | -$6.5M |
| Diluted EPS | -$0.59 | -$1.54 | -$0.73 | -$0.69 |
Tvardi Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.7M | $13.5M | $63.7M | $51.8M | $37.9M | $20.7M |
| Current Assets | $195.1M | $173.3M | $168.9M | $116.2M | $43.8M | $31.5M |
| Total Assets | $271.2M | $247.1M | $182.2M | $125.8M | $43.8M | $32.1M |
| Current Liabilities | $18.5M | $17.6M | $23.5M | $25.6M | $4.0M | $11.0M |
| Total Liabilities | $22.2M | $19.5M | $23.5M | $68.8M | $48.4M | $11.1M |
| Shareholders' Equity | $249.0M | $227.5M | $158.8M | $57.1M | -$4.6M | $20.9M |
Tvardi Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.5M | -$60.1M | -$78.7M | -$92.1M | -$60.9M | -$23.5M |
| Cash From Investing | -$20.3M | -$4.8M | $128.7M | $43.5M | $48.7M | -$10.1M |
| Cash From Financing | $39.1M | $46.6M | $311,000 | $38.2M | -$3.6M | $22.7M |
| Free Cash Flow | -$5.8M | -$60.1M | -$78.8M | -$94.5M | -$62.0M | -$23.5M |
Figures from Tvardi Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tvardi Therapeutics financials page for every line item.
Tvardi Therapeutics Company Profile
| Ticker | TVRD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Sugar Land, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001346830 |
Frequently Asked Questions
What was Tvardi Therapeutics' revenue in fiscal 2025?
Tvardi Therapeutics (TVRD) reported revenue of $0 for fiscal 2025.
What is Tvardi Therapeutics' annual revenue history?
Tvardi Therapeutics' annual revenue by fiscal year: 2020: $135.1M; 2021: $23.0M; 2022: $41.9M; 2023: $21.0M; 2024: $7.1M; 2025: $0.
What was Tvardi Therapeutics' net income in fiscal 2025?
Tvardi Therapeutics reported net income of -$18.2M for fiscal 2025.
What was Tvardi Therapeutics' earnings per share (EPS) in fiscal 2025?
Tvardi Therapeutics' diluted EPS was -$3.26 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tvardi Therapeutics generate in fiscal 2025?
Tvardi Therapeutics generated -$23.5M of free cash flow in fiscal 2025.
What was Tvardi Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tvardi Therapeutics reported revenue of $0.
How many shares of Tvardi Therapeutics are outstanding?
Tvardi Therapeutics reported a weighted average of 9.4 million basic shares outstanding in 2026 Q2.
What is Tvardi Therapeutics' market cap?
Based on its latest closing price, Tvardi Therapeutics (TVRD) has a market capitalization of about $9.8M.
When does Tvardi Therapeutics' fiscal year end?
Tvardi Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Tvardi Therapeutics headquartered?
Tvardi Therapeutics lists its business address in Sugar Land, Texas in its SEC filings.